SCHEMBL15412985

SCHEMBL15412985

C#CCOc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.69
CA9 Q16790 6/20 0.69
CA2 P00918 4/20 0.69
CA1 P00915 4/20 0.69
CA4 P22748 4/20 0.69
CA7 P43166 2/20 0.69
GSTP1 P09211 1/20 0.50
MAOA P21397 4/20 0.46
MAOB P27338 4/20 0.46
ACHE P22303 1/20 0.46
ENPP3 O14638 1/20 0.43
ADAM17 P78536 4/20 0.41
MMP1 P03956 3/20 0.41
MMP9 P14780 3/20 0.41
MMP13 P45452 3/20 0.41
PTGS2 P35354 1/20 0.41
CYP19A1 P11511 1/20 0.41
KAT6A Q92794 1/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16491168 0.81 CA12 (0.69) CA12CA9CA2CA1CA4
SCHEMBL16491167 0.81 CA2 (1.00) CA12CA9CA2CA1CA4
SCHEMBL24604554 0.81 CA12 (0.59) CA12CA9CA2CA1CA4
SCHEMBL719717 0.81 CA12 (0.69) CA12CA9CA2CA1CA4
SCHEMBL5704167 0.79 CA12 (0.63) CA12CA9CA2CA1CA4
SCHEMBL3848565 0.79 ADAM17 (0.63) ADAM17MMP1MMP9MMP13
SCHEMBL17676471 0.79 CA12 (0.65) CA12CA9CA2CA1CA4
SCHEMBL6275169 0.77 CA12 (0.44) CA12CA9CA2CA1CA4
Hydrochloric Acid SCHEMBL21694040 0.77 CA12 (0.61) CA12CA9CA2CA1CA4
SCHEMBL16473958 0.75 CA12 (0.59) CA12CA9CA2CA1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12366579-B2 Sulfur-heterocycle exchange chemistry and uses thereof UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-07-22 US disclosed
US-12018097-B2 Non-chromatographic purification of macrocyclic peptides by a resin catch and release BRISTOL-MYERS SQUIBB COMPANY (US) 2024-06-25 US disclosed
US-12018097-B2 Non-chromatographic purification of macrocyclic peptides by a resin catch and release BRISTOL-MYERS SQUIBB COMPANY (US) 2024-06-25 US disclosed
US-11479581-B2 Non-chromatographic purification of macrocyclic peptides by a resin catch and release BRISTOL-MYERS SQUIBB COMPANY (US) 2022-10-25 US disclosed
US-20220305121-A1 N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-09-29 US disclosed
US-20220214355-A1 SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-07-07 US disclosed
US-20220214355-A1 SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-07-07 US disclosed
CN-113853372-A Thio-heterocyclic exchange chemistry and uses thereof 弗吉尼亚大学专利基金委员会 2021-12-28 CN disclosed
EP-3924348-A2 SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF University of Virginia Patent Foundation (US) 2021-12-22 EP disclosed
US-20210079046-A1 NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE BRISTOL-MYERS SQUIBB COMPANY 2021-03-18 US disclosed
US-20160263234-A1 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2016-09-15 US disclosed
US-9315542-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-04-19 US disclosed
US-9309283-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-04-12 US disclosed
EP-2869820-A2 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS Onyx Therapeutics, Inc. (US) 2015-05-13 EP disclosed
US-20150051242-A1 RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) 2015-02-19 US disclosed
US-20150051242-A1 RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) 2015-02-19 US disclosed
US-20140105921-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors ONYX THERAPEUTICS, INC. 2014-04-17 US disclosed
US-20140100168-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors ONYX THERAPEUTICS, INC. 2014-04-10 US disclosed
US-20140100154-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors ONYX THERAPEUTICS, INC. (US) 2014-04-10 US disclosed
WO-2014011695-A2 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. (US) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140105921-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors PREP, VIP, PEPD CA12 1194/4885CA9 824/4885CA2 2908/4885
US-20210079046-A1 NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE ANPEP, DNPEP, NPR1 CA12 2754/4885CA9 2499/4885CA2 3509/4885
US-20220214355-A1 SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF TST, TPST2, SRMS CA12 3992/4885CA9 4162/4885CA2 3500/4885
US-11479581-B2 Non-chromatographic purification of macrocyclic peptides by a resin catch and release ANPEP, NPR1, DNPEP CA12 2922/4885CA9 2619/4885CA2 3615/4885
US-20140100168-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors PREP, VIP, PEPD CA12 1194/4885CA9 824/4885CA2 2908/4885
US-20160263234-A1 PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, VIP, PEPD CA12 1194/4885CA9 824/4885CA2 2908/4885
US-20140100154-A1 Prodrugs of Peptide Epoxy Ketone Protease Inhibitors PREP, VIP, PEPD CA12 1194/4885CA9 824/4885CA2 2908/4885
US-12018097-B2 Non-chromatographic purification of macrocyclic peptides by a resin catch and release VIP, NPR1, NPPA CA12 2593/4885CA9 2333/4885CA2 3731/4885
US-20150051242-A1 RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME RICTOR, MTOR, RPTOR CA12 3665/4885CA9 1816/4885CA2 3528/4885
US-12366579-B2 Sulfur-heterocycle exchange chemistry and uses thereof TST, TPST2, SRMS CA12 3992/4885CA9 4162/4885CA2 3500/4885
US-20220305121-A1 N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT TLR1, TLR3, TLR2 CA12 4726/4885CA9 4809/4885CA2 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.